tbuckley/cabot-search huggingface dataset:
<i>Diabetes Care</i>: “Lagniappe” and “Seeing Is Believing”!
Authors: William T. Cefalu, Andrew J.M. Boulton, William V. Tamborlane, Robert G. Moses, Derek LeRoith, Eddie L. Greene, Frank B. Hu, George Bakris, Judith Wylie-Rosett, Julio Rosenstock, Katie Weinger, Lawrence Blonde, Mary de Groot, Stephen S. Rich, David D’Alessio, Matthew C. Riddle, Lyn Reynolds
Journal: Diabetes Care (2016)

With this issue, our editorial team celebrates its 4.5-year mark in overseeing the scientific aspects of Diabetes Care . As you have come to expect, we have been consistent in our attempts to update you on our progress by informing you of all the changes, innovations, and successes of the journal. We still feel that each issue provides new information that does more than provide an incremental contribution to new knowledge—it also offers providers translational perspectives that relate new findings to everyday clinical practice and poses new questions to the research community.

We feel this past year has been nothing short of spectacular for the journal! A year ago, in the July 2015 issue, we titled our report “Status of Diabetes Care : New Challenges, New Concepts, New Measures—Focusing on the Future!” as we felt the journal was at that time very much on an uphill trajectory (1). In the January 2016 issue, we titled our report “Building Momentum: Taking on the Real ‘Issues’ of Diabetes Care !” (2). In that issue, we described what has become an incredibly well-received initiative at the journal: frequent special thematic monthly issues that focus on timely and important clinical care and clinical research topics.

The thematic issues to date, which at that time numbered 10, were summarized in a table in the January 2016 issue (2). For example, our October 2015 issue focused on the recommendations and other guidelines for care from the American Diabetes Association (ADA) in the form of Position Statements, Scientific Statements, and Consensus Reports, described collectively as “Guiding Principles for Diabetes Care” (3). We ended the calendar year by dedicating our December 2015 issue to highlight insulin use after 90 years (4). In that issue, we provided a collection of articles that demonstrated the diversity of recent innovations in …
Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy
Authors: Taisuke Matsuoka, Yoichiro Yoshida, Ai Mogi, Teppei Yamada, Naoya Aisu, Daibo Kojima, Syu Tanimura, Tomoko Koganemaru, Fumiaki Kiyomi, Yuichi Yamashita
Journal: Annals of Oncology (2015)
Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial
Authors: Dorien Reijnders, Gijs H. Goossens, Gerben D.A. Hermes, Evelien P.J.G. Neis, Christina M. van der Beek, Jasper Most, Jens J. Holst, Kaatje Lenaerts, Ruud S. Kootte, Max Nieuwdorp, Albert K. Groen, Steven W.M. Olde Damink, Mark V. Boekschoten, Hauke Smidt, Erwin G. Zoetendal, Cornelis H.C. Dejong, Ellen E. Blaak
Journal: Cell Metabolism (2016)
Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors
Authors: Paola Guglielmelli, Annalisa Pacilli, Giada Rotunno, Francesca Gesullo, Alessandro Pancrazzi, Lisa Pieri, Emanuela Sant'Antonio, Carmela Mannarelli, Giuseppe Loscocco, Chiara Paoli, Lucia Merli, Alessandro M. Vannucchi
Journal: Blood (2015)
Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units
Authors: Lyn S Chitty, David Wright, Melissa Hill, Talitha I Verhoef, Rebecca Daley, Celine Lewis, Sarah Mason, Fiona McKay, Lucy Jenkins, Abigail Howarth, Louise Cameron, Alec McEwan, Jane Fisher, Mark Kroese, Stephen Morris
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To investigate the benefits and costs of implementing non-invasive prenatal testing (NIPT) for Down's syndrome into the NHS maternity care pathway. <b>Design</b>&nbsp;Prospective cohort study. <b>Setting</b>&nbsp;Eight maternity units across the United Kingdom between 1 November 2013 and 28 February 2015. <b>Participants</b>&nbsp;All pregnant women with a current Down's syndrome risk on screening of at least 1/1000. <b>Main outcome measures</b>&nbsp;Outcomes were uptake of NIPT, number of cases of Down's syndrome detected, invasive tests performed, and miscarriages avoided. Pregnancy outcomes and costs associated with implementation of NIPT, compared with current screening, were determined using study data on NIPT uptake and invasive testing in combination with national datasets. <b>Results</b>&nbsp;NIPT was prospectively offered to 3175 pregnant women. In 934 women with a Down's syndrome risk greater than 1/150, 695 (74.4%) chose NIPT, 166 (17.8%) chose invasive testing, and 73 (7.8%) declined further testing. Of 2241 women with risks between 1/151 and 1/1000, 1799 (80.3%) chose NIPT. Of 71 pregnancies with a confirmed diagnosis of Down's syndrome, 13/42 (31%) with the diagnosis after NIPT and 2/29 (7%) after direct invasive testing continued, resulting in 12 live births. In an annual screening population of 698 500, offering NIPT as a contingent test to women with a Down's syndrome screening risk of at least 1/150 would increase detection by 195 (95% uncertainty interval −34 to 480) cases with 3368 (2279 to 4027) fewer invasive tests and 17 (7 to 30) fewer procedure related miscarriages, for a non-significant difference in total costs (£−46 000, £−1 802 000 to £2 661 000). The marginal cost of NIPT testing strategies versus current screening is very sensitive to NIPT costs; at a screening threshold of 1/150, NIPT would be cheaper than current screening if it cost less than £256. Lowering the risk threshold increases the number of Down's syndrome cases detected and overall costs, while maintaining the reduction in invasive tests and procedure related miscarriages. <b>Conclusions</b>&nbsp;Implementation of NIPT as a contingent test within a public sector Down's syndrome screening programme can improve quality of care, choices for women, and overall performance within the current budget. As some women use NIPT for information only, the Down's syndrome live birth rate may not change significantly. Future research should consider NIPT uptake and informed decision making outside of a research setting.
BMA annual meeting: Private firms shouldn’t use NHS logo, argue doctors
Authors: Zosia Kmietowicz
Journal: BMJ (2016)

Doctors have said that the BMA should lobby the government to stop private companies that provide NHS services, such as Serco, Circle, and Virgin, from using the NHS logo when they deliver NHS care.

Delegates at the BMA’s annual representatives meeting in Belfast, on 20 June, voted by 63% against 37% to pass the motion, proposed by Jacky Davis from Islington in London. She told the meeting, “The public does not want to see the …
Case 52-1962
Authors: William H. Baker, Benjamin Castleman
Journal: New England Journal of Medicine (1962)

Presentation of CaseA seventy-one-year-old man was admitted to the hospital for eye surgery because of a decrease in vision.One month previously the patient first noticed a black area in the nasal field of his vision, and during the next two weeks he complained of bright-red spots passing across the visual fields, but experienced no pain. Except for moderate fatigue and lassitude during the previous ten months he was otherwise generally well and continued to work part time as an electrician.Pain and swelling in the great toes and ankles developed twelve years before entry and recurred several times; . . .
It Is Time for Equal Pay for Equal Work for Physicians—Paging Dr Ledbetter
Authors: Vineet M. Arora
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Case 53-1969
Authors: Robert H. Schapiro, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of Case First admission. A sixty-one-year-old woman was admitted to the hospital because of recurrent hematemesis.Three months previously she had been admitted to another hospital after an episode of hematemesis. An upper gastrointestinal series was normal. A cholecystectomy was performed because of cholelithiasis. The liver was enlarged, and a biopsy showed changes interpreted as consistent with nutritional cirrhosis. She was given 6 units of whole blood and discharged. One month before entry another episode of hematemesis occurred and was treated at home. She was well thereafter until the morning of admission, when she vomited bright-red blood and passed . . .
Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy
Authors: Robert P. Jones, Graeme J. Poston
Journal: Annual Review of Medicine (2016)

About 25% of patients with colorectal cancer develop liver metastases after resection of the primary tumor, and surgical resection of the metastases offers the only opportunity for long-term survival. However, only 20% of patients present with resectable disease. Deciding which patients should be offered surgery, and which should receive additional treatment in the form of perioperative chemotherapy, is complex. For the majority of patients who present with technically irresectable liver-limited disease, systemic downsizing chemotherapy offers the only opportunity to reach surgery and potential cure. Molecular analysis of tumor tissue is improving patient stratification, allowing more appropriate treatment selection, but is not yet a regular part of clinical practice. Decision making is limited by a lack of clear prospective evidence, and so multidisciplinary team assessment is essential to optimize outcomes.
원저 : 각종 간질환에서 RT - PCR 을 이용한 G형 간염바이러스 RNA 의 검출률
Authors: 한광협, 최원, 박영년, 황영웅, 류왕식, 박은신, 이관식, 전재윤, 문영명, 박찬일 ( Kwang Hyub Han), Won Choi, Young Nyun Park, Young Woong Hwang, Wang Sik Ryu, Eun Sin Park, Kwan Sik Lee, Chae Yoon Chon, Young Myoung Moon, Chan Il Park
Journal: Clinical and Molecular Hepatology (1997)

Background/Aims: Recently, nucleotide sequences from a novel virus, termed hepatitis G virus (HGV), were identified in serum from a patient with cryptogenic hepatitis and suggested as agent of non A-E hepatitis. HGV has been isolated from patients with various liver diseases but clinical implications of this new agent remain largely unresolved. In Korea, the etiology of substantial fraction of hepatitis has remained undefined and there has been no report concerning HGV. Methods: To determine the infection rate of HGV, RT-PCR of 5 UTR of HGV was performed, and to understand the clinical implication of HGV, medical records of 115 patients with various liver diseases were reviewed. Of 115 patients, 63 were male and 52 were female. Their mean age was 44 years (19-74) and their mean AST and ALT were 121.3+278.7 IU/L and 172.2+253.3 IU/L, respectively. Of 115 patients, 58 (50.4%) had no specific cause of liver diseases, 37 (32.2%) were infected with hepatitis B and/or C virus and 20 (17.4%) had non-viral identifiable liver diseases. Results: 1. HGV RNA was detected in 15 (13.0%) patients of 115 patients. 2, Among the 15 HGV RNA positive cases, 7 were male and 8 were female. Their mean age was 48 years (19-72) and their mean AST and ALT were 71.9+45.2 IU/L, 97.4+66.8 IU/I respectively. 3. HGV RNA was detected in 8(13.8%) of 58 patients without obvious causes of their liver diseases and in 7 (18.9%) of 37 patients infected with HBV and/or HCV. However, HGV RNA was not detected fram 20 patients with non-viral liver diseases such as alcoholic liver diseases, autoimmune hepatitis,  PBC, or fatty liver. 4. HGV RNA was detected in 5 (19.2%) of 26 patients with acute hep- atitis, in 6 (9.4%) of 64 patients with chronic hepatitis, in 1 (14.3%) of 7 patients with liver cirrhasis, and iB 3 (27.3%) Of 11 pafients with hepatocellular caIcinoma. 5. These was no slatistically significant difference in sex, age, history of transfusion, serum ALT level, etiologies and status of liver diseases between HGV RNA positve and negative group. Conclusions: the prevalence of HGV infection is quite high among the patients who have no specific cause of acute or chronic liver diseases and HGV can be coinfected with HBV and/ar HCV infection in Korea.
Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial)
Authors: V. Adamo, G.R.R. Ricciardi, V. Franchina, G. Ferraro, M. Caruso, G. Bronte, G.L. Banna, P. Spadaro, A. Savarino, C. Iacono, H.J. Soto Parra, M. Spada, V. Safina, L. Blasi, F. Zerilli, A. Prestifilippo, C. Giannitto-Giorgio, D. Alberio, L. Cottini, A. Russo
Journal: Annals of Oncology (2015)
Transient Hemolytic and Thrombocytopenic Episode (? Acute Transient Thrombohemolytic Thrombocytopenic Purpura), with Probable Meningococcemia
Authors: Murray Nussbaum, William Dameshek
Journal: New England Journal of Medicine (1957)

THE clinical syndrome usually known as thrombotic thrombocytopenic purpura (more correctly, thrombohemolytic thrombocytopenic purpura) was first described by Moschcowitz1 in 1925. Since then, this rare entity has been reported many times and extensively reviewed.2 3 4 5 6 7 8 9 10 11 12 13 14 Although its etiologic basis is at present completely obscure, the disorder has been attributed to multiple immunologic mechanisms involving chiefly the red blood cells and the platelets, resulting in hemolytic anemia and multiple platelet thrombi, with complete or partial vascular occlusions in many organs of the body,2 or to a primary vasculitis of the smaller arterioles and capillaries,11 , 12 as in the collagen diseases. Meacham et al. . . .
Recommendations of the ESGE Workshop on Ethics in Gastrointestinal Endoscopy-Based Research
Authors: P Malfertheiner, G J Mantzaris, M Farhing, Y Niv, J Escourrou, G Treiber, F Di Mario, M A Reymond
Journal: Endoscopy (2003)

In recent years gastrointestinal endoscopy has emerged as a powerful clinical and research tool. The number of randomized controlled clinical trials whose selection criteria or outcome end points are based on endoscopic findings is steadily rising. In addition, novel endoscopic techniques are being developed and rapidly incorporated into routine clinical practice. All this implies research in healthy individuals and in patients. Gastrointestinal endoscopy-based research (GEBR) is by no means exempt from the ethical rules of medical research [1]. This article summarizes the recommendations of the workshop on the ethics of GEBR presented at the First European Symposium on Ethics in Gastroenterology and Digestive Endoscopy.
Phase II study of bi-weekly CPT-11+CDDP for patients with gastric cancer refractory to S-1 (OGSG 0504 study)
Authors: S. Nakae, M. Hirao, T. Kishimoto, S. Iijima, H. Ishida, T. Morimoto, M. Imano, M. Goto, N. Uedo, J. Fujita
Journal: Journal of Clinical Oncology (2008)

4571 Background: Chemotherapy has been widely used against advanced gastric cancer (AGC), however, the best treatment has not been confirmed. In 2007, S-1 showed the potential to be the standard treatment for AGC and stage II/III gastric cancer (Narahara et al. 2007 ASCO Abst.4514, Sasako et al. 2007 ASCO-GI Abst.8). CPT-11 has many reports showing the effectiveness as 2nd line treatment, and the combination therapy of CPT-11+CDDP available for outpatients is promising (Koizumi et al, Anticancer Res. 25:1257–62, 2005). Therefore, we performed a phase II study to evaluate CPT-11+CDDP as 2nd line after S-1 single agent failure. Methods: Eligible patients(pts) with histologically confirmed AGC, which was unresectable or metastatic became ineffective in S-1 as previous, an oral possible, an ECOG PS of 0- 2, an age of 20–75 years and adequate organ functions. The following treatment, CPT-11 60 mg/m2+ CDDP 30 mg/m2 iv on day 1, was repeated every 2 weeks until disease progression or appearance of unacceptable toxicity. Primary endpoint was response rate. Main secondary endpoints included toxicity, overall survival and time to progression. Based on planned sample size of 35 pts, the trial was designed to have 80% power to detect an improvement in response rate from 20 to 25% (2-sided log-rank test; significance level 0.05). Results: A total of 35 pts were enrolled in this trial between August 2005 and August 2007. The male/female was 30/5. The median age was 60 years (range 28–75 years). PS 0/1/2 was 21/10/4. All pts were evaluated for effectiveness and safety. In the itention-to-treat analysis, the overall response rate was 28.6%, including 4CR, 6PR, 13SD, 7PD,and 5NE. The most common grade 3/4 toxicities were: neutropenia(22.4%), hemoglobin(11.4%), anorxia(14.3%), fatigue(8.6%),and diarrhea(2.9%). The median overall survival was 450days at present. Conclusions: The combination treatment of CPT-11 and CDDP is feasible and effective. Accordingly, this regimen can be regarded as one of 2nd line standard treatment for gastric cancer. No significant financial relationships to disclose.
Case 14-1975
Authors: Ashby C. Moncure, Max L. Goodman
Journal: New England Journal of Medicine (1975)

Presentation of CaseA 33-year-old man was admitted to the hospital because of hoarseness and a left cervical mass.He was well until nine months previously, when he noticed a "hard feeling" in the throat, which recurred at intervals during the next three months. Six months before entry bronchitis developed, with a subsequent persistent cough productive of whitish sputum. One month later, while driving a car, he experienced a paroxysm of coughing that was followed by abrupt loss of consciousness, and he awoke to find his car in a ditch. There was no associated headache, muscle movement or incontinence. At . . .
First Report from the Saudi Bleeding Screening Study: Are Platelet Disorders More Common in Arabs?
Authors: Tarek Owaidah, Abdul Kareem M Al-Momen, Hazza A Alzahrani, Abdulmajeed Albanyan, Ayman Alsulaiman, Siddiqui Khawar, ALI Alzahrani, Mohammad al-Madani, Khalid AlSaleh, Saleh Mahsin
Journal: Blood (2015)
Cardiac Screening
Authors: Roger Chou
Journal: Annals of Internal Medicine (2015)

Letters21 July 2015Cardiac ScreeningRoger Chou, MDRoger Chou, MDFrom Oregon Health & Science University, Portland, Oregon.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L15-5112-2 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:As we described in the Methods section, our guideline on cardiac screening explicitly excluded preparticipation evaluation of athletes. Thus, the articles on screening of athletes that Dr. Zimmermann cited are not relevant. To clarify, Rubenstein and Greenfield (1) found that, in patients with chest pain who present to the emergency department, 5% (11 of 236) might have avoided an admission if a baseline ECG had been available. However, this percentage is a maximal estimate, because 9 of the 11 patients did not have a baseline ECG. In addition, how many admissions would have actually been avoided is unknown. ...References1. Rubenstein LZ, Greenfield S. The baseline ECG in the evaluation of acute cardiac complaints. JAMA. 1980;244:2536-9. [PMID: 7431589] CrossrefMedlineGoogle Scholar2. Hoffman JR, Igarashi E. Influence of electrocardiographic findings on admission decisions in patients with acute chest pain. Am J Med. 1985;79:699-707. [PMID: 4073107] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Roger Chou, MDAffiliations: From Oregon Health & Science University, Portland, Oregon.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1225. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCardiac Screening With Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging: Advice for High-Value Care From the American College of Physicians Roger Chou , for the High Value Care Task Force of the American College of Physicians* Cardiac Screening Paul Zimmermann Metrics 21 July 2015Volume 163, Issue 2Page: 151KeywordsDisclosureEmergency departmentGastroesophageal reflux diseaseHeart diseasesIschemiaScreening guidelinesYoung adults ePublished: 21 July 2015 Issue Published: 21 July 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Combination immunotherapy for cancer
Authors: Douglas Fearon
Journal: The Journal of Experimental Medicine (2016)

In this issue, Chapuis et al. describe the response of a single patient with metastatic melanoma to combination immunotherapy with anti-CTLA4 and adoptive T cell therapy (1). Although JEM usually discourages the submission of single case studies, the editors, like the authors, realized that this patient was unusual. He had previously been treated with anti-CTLA4 and adoptive T cell therapy administered as monotherapies, with only possible slowing of tumor growth with the former, and no response to the latter. The subsequent complete and durable clinical response to simultaneous treatment with these two modalities, therefore, allowed an argument to be made that their combination was responsible for the improved outcome.